All News
Valeant Acquires Brodalumab from Astra-Zeneca
Reuters reports that Valeant Pharmaceuticals International Inc (a Canadian Pharmaceutical company) is buying rights to AstraZeneca's late-stage experimental psoriasis drug, brodalumab, after it was dropped by codeveloper Amgen Inc in May. Amgen pulled out of the project b
Read Article
Advances in Uveitis Associated with Juvenile Arthritis
Uveitis is a common association of juvenile idiopathic arthritis (JIA) that has previously been characterized by poor visual prognosis with limited options for effective treatment.
Read Article
Increased Vascular Mortality in Ankylosing Spondylitis
Haroon et al has analyzed administrative claims data from Ontario, Canada and compared 21473 AS patients with 86606 normal comparators matched for age, sex, and location of residence.
Read Article
Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Read Article
Enthesitis Ultrasound as an Outcome Measure in Spondyloarthritis
Musculoskeletal ultrasound (US) was recently used in a longitudinal study Achilles enthesis of 146 patients with early spondyloarthritis (SpA). Usual measures of SpA activity included BASFI, BASRI-spine, BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS).
Read Article
Psoriasis Patients Satisfied with Biologics
A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy.
Read Article
DSB: Managing Methotrexate Toxicity
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
Read Article
International Psoriasis Council Publishes its Research Priorities
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Read ArticleMinority of Nonradiographic-Axial SpA Patients will Progress to Ankylosing Spondylitis
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
Read Article
AstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Read Article
Bidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Read Article
Psoriasis and Psoriatic Arthritis Have an Increased Risk of Gout
The frequency of gout among patients with psoriatic disease was studied in two cohorts of 98,810 patients from the Health Professionals Follow-up Study (1986-2010) and the Nurses' Health Study (1998-2010).
Read Article
The Use of Non-TNF Biologic Treatments in Uveitis Reviewed
A systematic review of treatments used in autoimmune chronic uveitis after failure of DMARDs and at least one TNF inhibitor identified few patients (12 children and 34 adults), and few trials examining rituximab (3), abatacept (3), tocilizumab (3), and 1 each with alemtuzumab and anakin
Read Article
Guselkumab Tops Adalimumab in Psoriasis Trial
NEJM reports a 52 week, phase II trial in 293 adult patients with moderate-to-severe psoriasis (>10 BSA) who were randomized to receive either placebo, adalimumab or guselkumab - a novel IL-23 inhibitor.
Read Article
Brodalumab Backlash
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Read Article
Neurologic Events with TNF Inhibitor Therapy
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
Read Article
What's Your Diagnosis? Hand Arthritis in 57 year old Man
A 57 year old male is referred for arthritis of the hands for the last 8 years. He complains of pain, swelling, stiffness in the fingers only. He denies rash, bowel, urologic or ocular complaints. Over-the-counter NSAIDs have provided only partial relief.
Read Article
TNF inhibitors in Early Axial SpA Spares NSAID Use
In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).
Read Article
Ustekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results
615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.
Read Article
Ustekinumab Bests TNF Inhibitors for Biologic Survival in Psoriasis
Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv
Read Article
